COMMUNIQUÉS West-GlobeNewswire

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
18/01/2024
Call scheduled for Monday, February 12th at 4:30 pm Eastern Time GARDEN CITY, N.Y., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device [...]
LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
18/01/2024
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced its participation in the Maxim Group 2024 Healthcare IT Virtual Conference, being held [...]
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
18/01/2024
Dr. Frederick to advise Company on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease (ILD). SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “ [...]
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18/01/2024
POMPANO BEACH, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to easing chronic pain without the use of opioids, and Sure Med Compliance, a digital healthcare company focused [...]
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
18/01/2024
PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial [...]
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
18/01/2024
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology [...]
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
18/01/2024
KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse model Evidence of greater than 40% editing of SERPINA1 RNA in non-human primates [...]
Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain
18/01/2024
SAN FRANCISCO and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related neurodegeneration. [...]
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
18/01/2024
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants
18/01/2024
LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt [...]
AURORA SPINE ANNOUNCES ATTENDANCE AT NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) ANNUAL MEETING
18/01/2024
CARLSBAD, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal [...]
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
18/01/2024
Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study BRAINTREE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Microbot [...]
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
18/01/2024
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean [...]
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
18/01/2024
Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: [...]
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
18/01/2024
- The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue Owl [...]
MedBright AI Reaches US$100M in Total Clinic Revenue Under Contract with MedMatrix, the AI-Powered Data Analytics Platform
18/01/2024
VANCOUVER, British Columbia, Jan. 18, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) has announced today that it has achieved its near term goal [...]
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
18/01/2024
WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, [...]
CENTOGENE Announces Preliminary Full Year 2023 Revenue
18/01/2024
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today [...]
Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck
18/01/2024
OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors Oxford, UK, San Jose, Calif ., 18 [...]

Pages